Clinical trials · Riverside–San Bernardino, CA
Refractory B Acute Lymphoblastic Leukemia clinical trials in Riverside–San Bernardino
We’re tracking 15 recruiting refractory b acute lymphoblastic leukemia studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Loma Linda, CaliforniaAges 12 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Loma Linda, CaliforniaAges Up to 22 years - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Upland, CaliforniaAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Orange, CaliforniaAges 1–21 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Orange, CaliforniaAges 18 years+ - NCT07133997RecruitingPhase 1
Combination therapy for relapsed CD19+ B-cell leukemia
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
Duarte, CaliforniaAges 12–55 - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 for adults and teens with relapsed B-ALL
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Duarte, CaliforniaAges 12 years+ - NCT04260022RecruitingPhase 1
Drug study for hard-to-treat CML or Ph+ ALL
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Duarte, CaliforniaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Duarte, CaliforniaAges 12 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Duarte, CaliforniaAges Up to 26 years - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT04150497RecruitingPhase 1/Phase 2
Testing a new cell therapy for CD22-positive leukemia
This trial tests UCART22, a new cell-based treatment, for people with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) that has the CD22 marker. It may help by attacking leukemia cells that carry CD22.
Los Angeles, CaliforniaAges 15–50 - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85
Hear when a new Refractory B Acute Lymphoblastic Leukemia trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Refractory B Acute Lymphoblastic Leukemia trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting refractory b acute lymphoblastic leukemia studies listed above.
- City of Hope Comprehensive Cancer Center · 9 studies
- Cedars-Sinai Medical Center · 2 studies
- Children's Hospital Los Angeles · 2 studies
- Children's Hospital of Orange County · 2 studies
- Loma Linda University Medical Center · 2 studies
- Research Site · 2 studies
- Children's Hospital Orange County
- City of Hope
What taking part in a refractory b acute lymphoblastic leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory b acute lymphoblastic leukemia studies in California.
Common questions
- Are there refractory b acute lymphoblastic leukemia clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 15 recruiting refractory b acute lymphoblastic leukemia studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory b acute lymphoblastic leukemia study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory b acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory b acute lymphoblastic leukemia studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.